House of Commons
As this motion is using historical data, we may not have the record of the original ordering, in which case signatories are listed alphabetically.
DRAFT NICE GUIDANCE FOR THE USE OF ABIRATERONE
EDM #2706
Tabled 08 February 2012
2010-12 Session
That this House notes with serious concern that the National Institute for Health and Clinical Excellence (NICE) has issued draft guidance for the use of the drug abiraterone, a life extending treatment for men in the final stages of prostate cancer, which could, if implemented, prevent the use of this cancer drug for the treatment of this condition in the NHS in England and Wales; is aware that prostate cancer is the most common cancer in men in the UK, that 32,500 men are diagnosed with prostate cancer and that 10,000 men die from the disease in England and Wales every year; further notes that abiraterone can extend the life of men in the final stages of prostate cancerby an average of four months and improves their quality of life; calls on the Government to act immediately to ensure that men with prostate cancer are able to access this treatment to treat their health condition and help to prolong their life; further calls on NICE to reconsider its draft guidance and recommend abiraterone for the benefit of men with prostate cancer and their families; and considers that men should be able to access this drug through the Cancer Drugs Fund, if their clinicians prescribe it, irrespective of this draft decision by NICE.

Signatures (35)

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.
In addition to the sponsors, the following Members have signed to support the motion.
There are no withdrawn signatures for this Motion